Video

MicroRNA-34a in Hepatocellular Carcinoma

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

A recent study suggests that microRNA-34a could have a role in regulating cytotoxicity and development of the effector NK cells.

MicroRNA-34a has been previously found to be downregulated in HCC—which is also associated with tumor progression—but it has never been explored in the NK cells of patients with HCC, says Abdelhamid.

Results showed that in the NK cells of patients with HCC, forcing microRNA34a expression significantly increased NKG2D and cytotoxic perforin-1 mRNA levels.

Clinical trials have begun to investigate whether microRNA-34a can be used as a tumor suppressor, Abdelhamid adds.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University